Cart
sales@molnova.com
CIA-1 (Free base)
CAS No. 452087-38-6
CIA-1 (Free base)( —— )
Catalog No. M36369 CAS No. 452087-38-6
CIA-1 (Free base) is a nuclear receptor COUP-TFII inhibitor with IC50 values ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 70 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 226 | In Stock |
|
| 50MG | 345 | In Stock |
|
| 100MG | 532 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCIA-1 (Free base)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCIA-1 (Free base) is a nuclear receptor COUP-TFII inhibitor with IC50 values ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines.
-
DescriptionCIA-1 (Free base) is a nuclear receptor COUP-TFII inhibitor with IC50 values ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines. CIA-1 (Free base) inhibits tumor growth in a mouse model of prostate cancer xenografts.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorGamma-secretase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number452087-38-6
-
Formula Weight329.42
-
Molecular FormulaC17H19N3O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(CCC1=CC(OC)=C(OC)C=C1)C2=C3C(SC(C)=C3)=NC=N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Jagged-1 188-204
This peptide is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-αB activation.
-
Rovalpituzumab
Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3) and is utilized to synthesize antibody-active molecule conjugates (ADCs).
-
Demcizumab
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.
